Although further studies are needed to clarify their safety and effectiveness, PAD inhibitors are potential candidates as novel therapeutic agents for various NET-related diseases, including MPO-ANCA-associated vasculitis. Here, PADI4 is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.